Nightfood Holdings, operating as TechForce Robotics, has announced a joint development, manufacturing and licensing agreement with Oncotelic Therapeutics to co-develop AI-enhanced, GMP-compliant robotic systems for pharmaceutical manufacturing and laboratory automation. The collaboration combines TechForce's robotics engineering with Oncotelic's AI-driven pharmaceutical technologies to target improved efficiency, compliance and scalability in biopharma production. This partnership represents TechForce's strategic expansion into regulated healthcare markets while leveraging Oncotelic CEO Dr. Vuong Trieu's extensive experience in oncology, drug development and AI-enabled innovation.
The agreement brings together two companies with complementary expertise in automation and pharmaceutical technology. TechForce Robotics, a wholly-owned subsidiary of Nightfood Holdings, is an AI-enhanced service-robotics and automation company focused on developing, deploying, and scaling autonomous robotic solutions. Through a vertically integrated platform that combines proprietary robotics technology, real-world operating environments, and scalable manufacturing, TechForce has been accelerating automation adoption across multiple industries. The company's initial sector of entry has been hospitality, where its Robotics-as-a-Service platform addresses repetitive, labor-intensive, and operationally constrained tasks.
Oncotelic Therapeutics brings specialized pharmaceutical knowledge to the partnership, particularly in oncology and AI-driven drug development. The collaboration aims to create robotic systems that meet Good Manufacturing Practice standards while incorporating artificial intelligence to optimize pharmaceutical production processes. This development comes as the biopharmaceutical industry faces increasing pressure to improve manufacturing efficiency, reduce costs, and ensure regulatory compliance while scaling production capabilities.
The joint development agreement covers multiple aspects of robotic system creation, including design, manufacturing, and licensing arrangements. By combining robotics engineering with pharmaceutical expertise, the partners seek to address specific challenges in laboratory automation and drug manufacturing that require both technical precision and regulatory understanding. The systems being developed are expected to help pharmaceutical companies streamline operations, reduce human error, and maintain consistent quality standards throughout production processes.
For investors following Nightfood Holdings, the latest news and updates relating to NGTF are available in the company's newsroom at http://ibn.fm/NGTF. The full press release about this partnership can be viewed at https://ibn.fm/aPEgr. This collaboration represents a significant step for TechForce Robotics as it expands beyond its initial hospitality focus into the highly regulated pharmaceutical sector, potentially opening new revenue streams and market opportunities for both companies involved in the partnership.
